We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+12.38%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$4.12B
AUM Growth
+$545M
Cap. Flow
+$493M
Cap. Flow %
11.96%
Top 10 Hldgs %
48.24%
Holding
158
New
26
Increased
23
Reduced
71
Closed
24

Top Buys

Rank Stock Value
1
KLRS
Kalaris Therapeutics
KLRS
+$69M
2
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$68.4M
3
BEKE icon
KE Holdings
BEKE
+$43.5M
4
IGMS
IGM Biosciences
IGMS
+$40.8M
5
ITOS
iTeos Therapeutics
ITOS
+$29.4M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$42.9M
2
PYPL icon
PayPal
PYPL
+$34.8M
3
AVTR icon
Avantor
AVTR
+$34M
4
ARGX icon
argenx
ARGX
+$30.2M
5
Z icon
Zillow
Z
+$22.1M

Sector Composition

Rank Sector Weight
1 Healthcare 57.47%
2 Consumer Discretionary 10.25%
3 Technology 2.5%
4 Real Estate 1.29%
5 Materials 0.75%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RPRX icon
76
Royalty Pharma
RPRX
$26.5B
$10.5M 0.26%
250,000
-500,000
-67% -$21.5M
KRYS icon
77
Krystal Biotech
KRYS
$10.8B
$10.2M 0.25%
237,500
+37,500
+19% +$1.63M
TCRR
78
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$10.2M 0.25%
500,000
+150,000
+43% +$2.63M
ESPR
79
DELISTED
Esperion Therapeutics
ESPR
$9.29M 0.23%
+250,000
New +$9.9M
STOK icon
80
Stoke Therapeutics
STOK
$1.84B
$9.07M 0.22%
270,750
-14,250
-5% -$407K
MCRB icon
81
Seres Therapeutics
MCRB
$45.2M
$8.49M 0.21%
+15,000
New +$4.99M
KYMR icon
82
Kymera Therapeutics
KYMR
$8.82B
$8.08M 0.2%
+250,000
New +$7.63M
APLT
83
DELISTED
Applied Therapeutics
APLT
$7.89M 0.19%
+380,000
New +$9.88M
DYN icon
84
Dyne Therapeutics
DYN
$4.19B
$7.47M 0.18%
+370,000
New +$8.12M
SYRE icon
85
Spyre Therapeutics
SYRE
$8.55B
$7.41M 0.18%
41,800
-2,200
-5% -$407K
PMVP icon
86
PMV Pharmaceuticals
PMVP
$57.6M
$7.1M 0.17%
+200,000
New +$7.36M
BRKR icon
87
Bruker
BRKR
$9.44B
$6.97M 0.17%
175,275
-9,225
-5% -$385K
SPRO icon
88
Spero Therapeutics
SPRO
$69.5M
$6.7M 0.16%
600,000
+54,960
+10% +$650K
ARAV
89
DELISTED
Aravive, Inc. Common Stock
ARAV
$6.16M 0.15%
1,311,291
-69,015
-5% -$490K
AAL icon
90
CALL
American Airlines Group
AAL
$10B
$6.14M 0.15%
500,000
– –
RGNX icon
91
Regenxbio
RGNX
$626M
$6.12M 0.15%
222,300
-11,700
-5% -$381K
PRQR icon
92
ProQR Therapeutics
PRQR
$251M
$5.73M 0.14%
1,196,218
-62,959
-5% -$329K
HOOK
93
DELISTED
HOOKIPA Pharma
HOOK
$5.68M 0.14%
59,962
– –
CYPH
94
Cypherpunk Technologies Inc
CYPH
$64.9M
$5.59M 0.14%
282,530
-14,870
-5% -$287K
KLDO
95
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$5.54M 0.13%
500,500
– –
ALPN
96
DELISTED
Alpine Immune Sciences Inc
ALPN
$5.21M 0.13%
+593,030
New +$5.42M
APTX
97
DELISTED
Aptinyx Inc. Common Stock
APTX
$5.08M 0.12%
1,502,035
-79,055
-5% -$303K
VXRT
98
DELISTED
Vaxart
VXRT
$4.99M 0.12%
750,000
+550,000
+275% +$4.9M
ACIU icon
99
AC Immune
ACIU
$233M
$4.88M 0.12%
1,000,000
+15,450
+2% +$111K
ADPT icon
100
Adaptive Biotechnologies
ADPT
$3.59B
$4.86M 0.12%
100,000
-88,000
-47% -$3.7M
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q3 2020 Portfolio in Review

As of Q3 2020, Artal Group held 158 positions worth $4.12B, up 15% from $3.57B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Artal Group deployed $493M of net new capital in Q3 2020, opening 26 new positions and adding to 23 existing holdings. Its largest new stake was Kalaris Therapeutics: 101,016 shares worth $63.9M.

By sector, the portfolio is most concentrated in Healthcare at 57% of assets, down from 62% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was argenx, an estimated $30.2M trimmed.

  • Artal Group's largest Q3 2020 buy was Kalaris Therapeutics: 101,016 shares worth $63.9M.
  • Artal Group added most to Agenus in Q3 2020, an estimated $16.1M increase.
  • Artal Group's biggest Q3 2020 reduction was argenx, cutting an estimated $30.2M.
  • Artal Group fully exited Blueprint Medicines in Q3 2020, selling an estimated $42.9M.
  • Artal Group's ten largest holdings make up 48% of its $4.12B portfolio in Q3 2020.
  • Artal Group opened 26 new positions and closed 24 in Q3 2020.
  • Artal Group's portfolio value rose 15% quarter-over-quarter to $4.12B.

Based on Artal Group's 13F filing for Q3 2020, filed 13 Nov 2020.